國藥現代(600420.SH):控股子公司通過德國EU-GMP認證
格隆匯1月17日丨國藥現代(600420.SH)公佈,控股子公司國藥集團致君(深圳)製藥有限公司(簡稱國藥致君),收到德國相關監管機構(BundesinstitutfürArzneimittelundMedizinprodukte,簡稱BfArM)頒發的GMP證書,國藥致君粉針一車間1線首次通過EU-GMP符合性檢查。本次國藥致君生產線通過EU-GMP認證,表明國藥致君在質量管理體系和生產環境設施等方面得到了BfArM的許可,有利於公司進一步拓寬國際規範市場銷售,提高公司的綜合競爭力,對公司未來經營產生積極作用。上述事項對公司目前經營業績不會產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.